Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients with Previously Treated mCRPC By Ogkologos - April 9, 2025 491 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-921 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Melphalan October 1, 2020 The Nobel Prize winner helping us treat children’s cancers November 8, 2022 How My Cancer Diagnosis at Age 17 Changed My Perspective on... December 14, 2020 ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) July 28, 2020 Load more HOT NEWS Man Becomes Nervous About How Cop Acts During Ticket, Then He... Individualised Nutritional Support Reduce the Risk of Mortality in Cancer Patients... Short-Term Radiotherapy with Preoperative Chemotherapy Followed by Surgery is Efficacious with... New drug combo for advanced breast cancer approved for NHS in...
